Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708278 · ClinicalTrials.gov registry record · Phase 1
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01708278: Completed Phase 1 study, sponsored by University of Michigan.
NCT01708278 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01708278, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA. Current therapies for COPD are only partially effective and may also have side effects. Although increasing evidence indicates that quercetin supplementation may be beneficial in treating COPD, key methodological issues have not been resolved. The overall objective of this study is to determine the dosage of quercetin supplementation, bioavailability of quercetin, safety, dose-response relationship and appropriate biomarkers which reflect clinical outcomes in patients with COPD that is necessary for conducting large clinical trials in this patient population.
Primary Outcome
Note: If values for any of the measures indicated here were found, the participant would be indicated as a participant with a safety concern, and values for that particular measure would be posted specifically, but since none of the participants experienced these outlying values, results of all tests are expressed here as a composite function. PULMONARY FUNCTION TEST: FEV1% of predicted: decline by \>20% from baseline COMPLETE BLOOD COUNTS: WBC (cells)/mm3 : \<2000, Platelets (cells)/mm3: \<25
Interventions
- DRUG Quercetin
- OTHER Placebo - sugar chew
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
What the finished NCT01708278 record still lists
NCT01708278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Quercetin is the first listed.
NCT01708278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01708278 about?
NCT01708278 is a clinical study titled "Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)". Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA. Current therapies for COPD are only partially effective and may also have side effects. Although increasing evidence indicates that quercet...
What is the current status of trial NCT01708278?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01708278?
The interventions under investigation include: Quercetin (DRUG), Placebo - sugar chew (OTHER).
Who is sponsoring clinical trial NCT01708278?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01708278's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia